GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.

Sascha MarxFabian WilkenIsabel WagnerMadlen Marx Sascha Troschke-Meurer Maxi ZumpeSandra Bien-MoellerMartin WeidemeierJoerg BaldaufSteffen K FleckBernhard H RauchHenry W S SchroederHolger N Lode Nikolai Siebert

Published in: Journal of neuro-oncology (2020)

Our present data show anti-tumor effects mediated by dinutuximab beta against GBM cells providing a rationale for a GD2-directed immunotherapy against GBM. Due to high CRP expression, a combining of GD2-targeting with CRP blockade might be a further treatment option for GBM.

Keyphrases

induced apoptosis
cancer therapy
poor prognosis
cell cycle arrest
clinical trial
electronic health record
big data
binding protein
oxidative stress
combination therapy
drug delivery
cell proliferation